

NOTE

¹³C-NMR STUDIES ON THE BIOSYNTHESIS OF AURODOX (ANTIBIOTIC X-5108)

CHAC-MIN LIU, THOMAS H. WILLIAMS
and ROSS G. PITCHER

Chemical Research Department
Hoffmann-La Roche Inc.
Nutley, New Jersey 07110, U.S.A.


(Received for publication December 23, 1978)


Biosynthetic studies¹⁾ using ¹⁴C-labelled substrates have shown that aurodox (I) is assembled

by *Streptomyces goldiniensis* from acetate, propionate, and butyrate units, and a C₁ donor such as methionine or glycine. Chemical degradations of ¹⁴C-aurodox derived from these substrates suggest that the backbone of the antibiotic contains carbons from both a butyrate and a propionate unit, and that four of the five branched methyls are formed by transmethylation, including the geminal methyls at C-32.

In order to gain further insight into the biosynthesis of the antibiotic, ¹³C-precursors (at 1.0 g/liter) have been used as substrate in *S. goldiniensis* fermentations to yield acetate-1-¹³C,

Fig. 1. ¹³C-NMR Spectra of aurodox in deuteriomethanol (CD₃OD).
A. Butyrate-1,4-¹³C derived aurodox.
B. Butyrate-1-¹³C derived aurodox.
C. Natural abundance.





-2- ^{13}C ; propionate-1- ^{13}C , -3- ^{13}C ; butyrate-1- ^{13}C , -1,4- ^{13}C and methionine-methyl- ^{13}C derived aurodox. Comparison of the FT-proton noise decoupled ^{13}C -NMR spectrum of natural abundance with that of butyrate-1- ^{13}C derived antibiotic (Fig. 1) indicated 3.5-fold primary enrichment of the downfield peak at 177.9 ppm assigned to C-27 (the amide carbonyl group of the antibiotic molecule). The spectrum of butyrate-1,4- ^{13}C derived aurodox revealed two major en-

richment sites at $\delta=177.9$ (8~10 fold enrichment) and at $\delta=12.4$ ppm (3~4 fold enrichment), the latter due to C-46 (the CH_3 of the ethyl group at C-28). These results confirm our previous finding

that an intact butyrate unit is incorporated into aurodox to constitute the C-46, C-45, C-28 and C-27 part of the molecule. This is one of the few examples of an intact butyrate unit being incorporated into a polyketide to form a C-ethyl group; the polyether antibiotics lasalocid and monensin are other known examples^{2,3}. Propionate is also incorporated as an intact unit as shown by an 8-fold enrichment at $\delta=202$ ppm (C-7), and a 5.5-fold enrichment at $\delta=12.1$ ppm

Fig. 2. ^{13}C -NMR Spectra of aurodox in deuteriomethanol (CD_3OD).
 A. Propionate-3- ^{13}C derived aurodox.
 B. Propionate-1- ^{13}C derived aurodox.
 C. Natural abundance.




Table 1. Incorporation of acetate-1-¹³C into aurodox as determined by ¹³C-NMR.

Chemical shift ppm TMS	Enrichment × natural abundance	Assignment	Functional group
178.2	2.1	C-2	N-C=O
165.0	7.3	C-4	=C-OH
141.4	5.7	C-6	=CH-N
140.0	8.5	C-9, C-36	* } =CH-
135.9(2C)	4	C-11, C-38	
131.1(2C)	10.6	C-13	
127.7	11.7	C-22	
126.3	9.8	C-24	
101.0	4.7	C-29	
92.1	9.8	C-15	} -CH-O
85.3	9.7	C-17	
77.4	6.9	C-20	
75.0	9.2	C-31	
74.1	3.9	C-33	

* Signals in the bracket are assigned as a group.

(C-41) in aurodox derived from propionate-1-¹³C and -3-¹³C respectively (Fig. 2).

The extent of enrichment by acetate-1-¹³C, acetate-2-¹³C and methionine-methyl-¹³C is shown in Table 1 and Table 2. Carbons bearing oxygen, methine and methyl carbons are assigned on the basis of their chemical shift. Rigorous assignment of individual carbon atom resonances will require further study, but an outline of the incorporation pattern for the antibiotic can now be proposed. The spectrum of acetate-1-¹³C derived aurodox had 16 signals enriched (C-2, 4, 6, 9, 11, 13, 15, 17, 20, 22, 24, 29, 31, 33, 36, and C-38), whereas acetate-2-¹³C derived aurodox exhibited 14 enrichment peaks at C-10, 12, 14, 16, 19, 21, 23, 25, 30, 32, 35, 37, 39, and C-43. From the methionine-methyl-¹³C labelling experiment the O-methyl (C-43), N-methyl (C-40) and four C-methyls (C-42, 44, 47 and C-48) were all found to be enriched.

The labelling experiments carried out so far account for 39 out of 44 carbons of the aurodox molecule. Of the five unenriched carbons, C-8, C-45, and C-28 can be expected to arise from propionate and butyrate, leaving only C-3 and C-5

Table 2. Incorporation of acetate-2-¹³C and methionine-CH₃-¹³C into aurodox as determined by ¹³C-NMR.


Chemical shift ppm TMS	Enrichment × natural abundance	Assignment	Functional group
Actate-2- ¹³ C derived			
135.9	2.6	C-21	=C-Me
133.9	3.4	C-10, C-37	* } =CH-
130.6(2C)	5.7	C-12	
130.2	4.5	C-23	
128.3	6.5	C-35	
81.8	6.0	C-14	} -CH-O
74.1	2.6	C-16	
71.5	3.3	C-30	
56.3	2.3	C-43	O-CH ₃
42.1	2.0	C-25	N-CH ₂ -
40.0	4.3	C-32	-C(Me) ₂ -
37.0	5.2	C-19	-CH(Me)-
13.7	5.5	C-39	C-CH ₃
Methionine-CH ₃ - ¹³ C derived			
56.3	33	C-43	O-CH ₃
36.6	24	C-40	N-CH ₃
24.7	11	C-42	} C-CH ₃
15.9	12	C-44	
12.4	14	C-47	
11.3	20	C-48	

* Signals in the bracket are assigned as a group.

to be accounted for. The carbon skeleton of the antibiotic molecule appears to be formed by the joining of two polyketide fragments joined by an amide bond. One fragment is derived from 5 acetate and one butyrate unit, the other from one propionate and 8 acetate units (Fig. 3). The sequence of C-methylation as well as O- and N-methylation remains to be determined.

The biosynthetic origin of the pyridone moiety is unclear. Although C-2, C-4 and C-6 can be derived from the carbonyl group of acetate, feeding of acetate-2-¹³C failed to enrich C-3 and

Fig. 3. Hypothetical biosynthetic origin of the aurodox carbon skeleton.



C-5 as would be expected if intact acetate units were incorporated into the pyridone moiety. Previously, we have shown that cadaverine-1,5-¹⁴C, and L-aspartic acid-U-¹⁴C were poorly incorporated into aurodox (about 0.5%), and quinolinic acid-6-¹⁴C and nicotinic acid-7-¹⁴C were not incorporated at all. In this connection, it is of interest to note that the pyridone moiety of the antibiotic tenellin was found to be derived from an acetate unit and the alanine moiety of phenylalanine⁴.

Acknowledgements

We wish to thank Dr. J. W. WESTLEY and Dr. P. A. MILLER for useful discussions.

References

- 1) LIU, C.-M.; H. MAEHR, M. LEACH, M. LIU & P. A. MILLER: Biosynthesis of aurodox (Antibiotic X-5108). Incorporation of ¹⁴C-labelled precursors into aurodox. *J. Antibiotics* 30: 416~419, 1977
- 2) WESTLEY, J. W.; D. L. PRUESS & R. G. PITCHER: Incorporation of (1-¹³C)butyrate into antibiotic X-537A. *J. Chem. Soc., Chem. Comm.* 1972: 161~162, 1972
- 3) DAY, L. E.; J. W. CHAMBERLIN, E. Z. GORDEE, S. CHEN, M. GORMAN, R. L. HAMILL, T. NESS, R. E. WEEKS & R. STROSHANE: Biosynthesis of monensin. *Antimicrob. Agents & Chemother.* 4: 410~414, 1973
- 4) MCINES, A. G.; D. G. SMITH, J. A. WALTER, L. C. VINING & J. L. C. WRIGHT: New techniques in biosynthetic studies using ¹³C nuclear magnetic resonance spectroscopy. The biosynthesis of tenellin enriched from singly and doubly labelled precursors. *J. Chem. Soc., Chem. Comm.* 1974: 282~284, 1974